BMS Makes The Case For A Lasting Hematology Legacy

ASH Meeting Will Highlight Key Growth Products

Red Blood Cells and T-Cells floating through blood vessels 3d rendering
Bristol's hematology product revenue jumped from $2.5bn in 2019 to $18.1bn in 2020 after it bought Celgene • Source: Alamy

More from Clinical Trials

More from R&D